Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors
Status:
Completed
Trial end date:
2007-05-08
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to document the safety of the combination (escalation
doses of NGR-hTNF, from 0.2 mcg/sqm to 1.6 mcg/sqm , with a fixed dose of doxorubicin, 75
mg/sqm). Safety will be established by clinical and laboratory assessment according to
National Cancer Institute Common Toxicity Criteria (NCI-CTC ).